Literature DB >> 22516254

Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML.

Alyson A Lokken1, Nancy J Zeleznik-Le.   

Abstract

KDM1A/LSD1, a histone H3K4/K9 demethylase and epigenetic regulator with roles in both gene activation and repression, has increased expression in multiple cancer types. Harris et al., in this issue of Cancer Cell, and Schenk et al. show that KDM1A may be a viable therapeutic target in treating AML.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 22516254      PMCID： PMC3996681          DOI： 10.1016/j.ccr.2012.03.027

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  CoREST is an integral component of the CoREST- human histone deacetylase complex.

Authors:  A You; J K Tong; C M Grozinger; S L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

2.  ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation.

Authors:  Tatsuya Nakamura; Toshiki Mori; Shinichiro Tada; Wladyslaw Krajewski; Tanya Rozovskaia; Richard Wassell; Garrett Dubois; Alexander Mazo; Carlo M Croce; Eli Canaani
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

3.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.

Authors:  Tino Schenk; Weihsu Claire Chen; Stefanie Göllner; Louise Howell; Liqing Jin; Katja Hebestreit; Hans-Ulrich Klein; Andreea C Popescu; Alan Burnett; Ken Mills; Robert A Casero; Laurence Marton; Patrick Woster; Mark D Minden; Martin Dugas; Jean C Y Wang; John E Dick; Carsten Müller-Tidow; Kevin Petrie; Arthur Zelent
Journal:  Nat Med       Date:  2012-03-11       Impact factor: 53.440

4.  Opposing LSD1 complexes function in developmental gene activation and repression programmes.

Authors:  Jianxun Wang; Kathleen Scully; Xiaoyan Zhu; Ling Cai; Jie Zhang; Gratien G Prefontaine; Anna Krones; Kenneth A Ohgi; Ping Zhu; Ivan Garcia-Bassets; Forrest Liu; Havilah Taylor; Jean Lozach; Friederike L Jayes; Kenneth S Korach; Christopher K Glass; Xiang-Dong Fu; Michael G Rosenfeld
Journal:  Nature       Date:  2007-03-28       Impact factor: 49.962

5.  Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers.

Authors:  Shinya Hayami; John D Kelly; Hyun-Soo Cho; Masanori Yoshimatsu; Motoko Unoki; Tatsuhiko Tsunoda; Helen I Field; David E Neal; Hiroki Yamaue; Bruce A J Ponder; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

6.  The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.

Authors:  William J Harris; Xu Huang; James T Lynch; Gary J Spencer; James R Hitchin; Yaoyong Li; Filippo Ciceri; Julian G Blaser; Brigit F Greystoke; Allan M Jordan; Crispin J Miller; Donald J Ogilvie; Tim C P Somervaille
Journal:  Cancer Cell       Date:  2012-03-29       Impact factor: 31.743

7.  Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.

Authors:  Debabrata Biswas; Thomas A Milne; Venkatesha Basrur; Jaehoon Kim; Kojo S J Elenitoba-Johnson; C David Allis; Robert G Roeder
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-06       Impact factor: 11.205

8.  Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.

Authors:  Yujiang Shi; Fei Lan; Caitlin Matson; Peter Mulligan; Johnathan R Whetstine; Philip A Cole; Robert A Casero; Yang Shi
Journal:  Cell       Date:  2004-12-29       Impact factor: 41.582

9.  LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.

Authors:  Eric Metzger; Melanie Wissmann; Na Yin; Judith M Müller; Robert Schneider; Antoine H F M Peters; Thomas Günther; Reinhard Buettner; Roland Schüle
Journal:  Nature       Date:  2005-08-03       Impact factor: 49.962

Review 10.  A genecentric Human Protein Atlas for expression profiles based on antibodies.

Authors:  Lisa Berglund; Erik Björling; Per Oksvold; Linn Fagerberg; Anna Asplund; Cristina Al-Khalili Szigyarto; Anja Persson; Jenny Ottosson; Henrik Wernérus; Peter Nilsson; Emma Lundberg; Asa Sivertsson; Sanjay Navani; Kenneth Wester; Caroline Kampf; Sophia Hober; Fredrik Pontén; Mathias Uhlén
Journal:  Mol Cell Proteomics       Date:  2008-10       Impact factor: 5.911
  10 in total
  21 in total

Review 1.  Epigenetics in the hematologic malignancies.

Authors:  Chun Yew Fong; Jessica Morison; Mark A Dawson
Journal:  Haematologica       Date:  2014-12       Impact factor: 9.941

Review 2.  Childhood acute myeloid leukaemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba
Journal:  Br J Haematol       Date:  2012-09-12       Impact factor: 6.998

Review 3.  Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential.

Authors:  Ly P Vu; Luisa Luciani; Stephen D Nimer
Journal:  Int J Hematol       Date:  2013-01-04       Impact factor: 2.490

Review 4.  Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia.

Authors:  Paolo Gallipoli; George Giotopoulos; Brian J P Huntly
Journal:  Ther Adv Hematol       Date:  2015-06

Review 5.  Epigenetic regulation of LSD1 during mammary carcinogenesis.

Authors:  Yadi Wu; Binhua P Zhou
Journal:  Mol Cell Oncol       Date:  2014-12-23

6.  Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner.

Authors:  Lihua Jin; Christin L Hanigan; Yu Wu; Wei Wang; Ben Ho Park; Patrick M Woster; Robert A Casero
Journal:  Biochem J       Date:  2013-01-15       Impact factor: 3.857

7.  Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells.

Authors:  Han Han; Xiaojing Yang; Kurinji Pandiyan; Gangning Liang
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

8.  KDM1 is a novel therapeutic target for the treatment of gliomas.

Authors:  Gangadhara R Sareddy; Binoj C Nair; Samaya K Krishnan; Vijay K Gonugunta; Quan-guang Zhang; Takayoshi Suzuki; Naoki Miyata; Andrew J Brenner; Darrell W Brann; Ratna K Vadlamudi
Journal:  Oncotarget       Date:  2013-01

9.  Epigenetic control and cancer: the potential of histone demethylases as therapeutic targets.

Authors:  Fernando Lizcano; Jeison Garcia
Journal:  Pharmaceuticals (Basel)       Date:  2012-09-12

10.  The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.

Authors:  Lina Yang; Li Liu; Hong Gao; Jaya Pratap Pinnamaneni; Deepthi Sanagasetti; Vivek P Singh; Kai Wang; Megumi Mathison; Qianzi Zhang; Fengju Chen; Qianxing Mo; Todd Rosengart; Jianchang Yang
Journal:  J Hematol Oncol       Date:  2017-10-03       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.